IMMX:NASDAQImmix Biopharma, Inc. Analysis

Immix Biopharma (IMMX) is trading at $9.25, just above its 20‑day SMA of $9.20 and comfortably above the 50‑day SMA of $8.39, signaling short‑term bullish momentum. The RSI sits near 53, indicating neutral pressure, while the MACD histogram is negative and the MACD line sits below its signal, suggesting a near‑term bearish tilt despite the broader bullish trend. Volatility is extreme at 93% over the past 30 days and beta exceeds 1.4, underscoring heightened price swings.
Fundamentally, the company has no revenue and is burning cash, with negative EBITDA and free cash flow, yet it holds over $100 M in cash and a negligible debt load. Analyst consensus is strongly positive (5 analysts, “strong_buy”) with a mean target of $17.56, implying roughly 90% upside. Recent material news includes an amendment to a $100 M at‑the‑market offering and coverage initiations from Citizens and Morgan Stanley, which could fund continued clinical development and add liquidity.